NCT00061945 - Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | Biotech Hunter

Enrollment

302

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

December 31, 2007

Study Completion Date

October 31, 2012

Conditions

Acute Undifferentiated LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaL1 Adult Acute Lymphoblastic LeukemiaL1 Childhood Acute Lymphoblastic LeukemiaL2 Adult Acute Lymphoblastic LeukemiaL2 Childhood Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic LeukemiaT-cell Adult Acute Lymphoblastic LeukemiaT-cell Childhood Acute Lymphoblastic LeukemiaUntreated Adult Acute Lymphoblastic LeukemiaUntreated Childhood Acute Lymphoblastic Leukemia

Interventions

DRUG

allopurinol

Given PO

DRUG

cyclophosphamide

Given IV

DRUG

daunorubicin hydrochloride

Given IV

DRUG

vincristine sulfate

Given IV

DRUG

dexamethasone

Given PO and as eye drops

DRUG

asparaginase

Given SC

BIOLOGICAL

filgrastim

Given SC

DRUG

imatinib mesylate

Given PO

DRUG

methotrexate

Given IT, IV, and PO

DRUG

cytarabine

Given IV

DRUG

trimethoprim-sulfamethoxazole

Given PO

DRUG

mercaptopurine

Given PO

DRUG

leucovorin calcium

Given IV and PO

BIOLOGICAL

alemtuzumab

Given SC

DRUG

acyclovir

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH